Aclaris Therapeutics Inc. is cutting 86 staff as part of a restructuring to refocus resources on the development of its drug pipeline.
The Wayne, Pa.-based biopharmaceutical company, which develops and commercializes treatments for skin disorders and immuno-inflammatory diseases, said it is also seeking partners for its commercial products business.
Aclaris said it will not use a sales force to promote Rhofade and is looking for strategic partners for Eskata and its experimental topical solution for common warts, A-101.
Additionally, the company is seeking a development and commercialization partner for ATI-501 and ATI-502, drug candidates for treating a hair loss condition.
Aclaris will pursue the development of another treatment, ATI-450, for rheumatoid arthritis, and will keep investing in ATI-1777 and other preclinical drug candidates for immuno-inflammatory diseases.
The total restructuring cost will be in the range of $3 million to $3.5 million, Aclaris noted in its Sept. 5 press release.
